Gsk (GLAXF) Asset Writedowns and Impairment (2016 - 2017)
Gsk (GLAXF) recorded quarterly Asset Writedowns and Impairment of -$228.4 million in Q4 2017, down 1048.02% quarter-over-quarter from -$19.9 million in Q4 2016, and down 1048.02% on a YoY basis from $24.1 million in Q4 2016.
Gsk (GLAXF) Asset Writedowns and Impairment (2016 - 2017) Analysis & Trends
Gsk's Asset Writedowns and Impairment history runs 2 years deep, the most recent figure standing at -$228.4 million for Q4 2017.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn |
| 10 | Gsk | - | - | 7.76 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2017 | -228.36 Mn |
| Dec 31, 2017 | -228.36 Mn |
| Dec 31, 2016 | -19.89 Mn |
| Dec 31, 2016 | -19.89 Mn |